Jupiter Neurosciences secures $100M term sheet for ALA-002 MDMA rights

Jupiter Neurosciences entered into a term sheet to acquire exclusive U.S. rights to PharmAla's ALA-002, a next-generation MDMA therapeutic, with an upfront payment of $3.33 million and milestone payments. The transaction positions the company to capitalize on President Trump's executive order accelerating psychedelic medicine development and approval pathways.